

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 June 2001 (28.06.2001)

PCT

(10) International Publication Number
WO 01/46404 A1

(51) International Patent Classification⁷: C12N 15/10, C12Q 1/68

(74) Agents: YASGER, Paul, D. et al.; D377/AP6D, 100 Abbott Park Road, Abbott Park, IL 60064-6050 (US).

(21) International Application Number: PCT/US00/34997

(81) Designated States (*national*): CA, JP.

(22) International Filing Date:
21 December 2000 (21.12.2000)

(84) Designated States (*regional*): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

(25) Filing Language: English

(26) Publication Language: English

Published:

— With international search report.

— Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.


(30) Priority Data:
09/470,944 22 December 1999 (22.12.1999) US

(71) Applicant: ABBOTT LABORATORIES [US/US];
D377/AP6D, 100 Abbott Park Road, Abbott Park, IL 60064-6050 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventor: GUNDLING, Gerard, J.; 153 Wildwood Road, Lake Forest, IL 60045 (US).

(54) Title: NUCLEIC ACID ISOLATION METHOD AND KIT



(57) Abstract: Provided herein is a method for separating nucleic acid from a test sample comprising the steps of contacting a test sample with a metal oxide support material and a binding buffer to form nucleic acid/metal oxide support material complexes, separating the complexes from the test sample; and eluting the nucleic acid from the metal oxide support material.

WO 01/46404 A1

NUCLEIC ACID ISOLATION METHOD & KIT

Field of the Invention

The present invention relates to methods and kits for isolating nucleic acid and more particularly relates to methods and kits for isolating nucleic acids that do not use significant concentrations of flammable components.

Background of the Invention

Several methods for isolating nucleic acid from various sources are well known. Early methods employed organic solvents, such as phenol and/or chloroform, to selectively precipitate and then remove proteins from a nucleic acid containing solution. Once the protein was removed, dissolved nucleic acid then could be precipitated using alcohol and collected on a solid surface. An appropriate buffer then was used to solubilize the nucleic acid and thereby remove it from the solid surface.

As previously mentioned, early methods for purifying nucleic acid sequences typically employed organic solvents to differentially precipitate nucleic acid sequences from proteins and other undesired matter found in a source material. Once precipitated, the nucleic acid is easily collected on solid a substrate such as a glass stir rod before it is solubilized in a purified state. The affinity nucleic acid displays for solid substrates in the presence of a chaotropic agent has also been exploited to purify nucleic acid. These sample prep methods in addition to employing chaotropic agents typically use organic solvents, such as an alcohol, to assure that the nucleic acid binds the solid substrate or stays bound to the substrate during washing procedures. While such procedures use relatively low concentrations of organic solvents, in comparison to early methods of isolating nucleic acid where organic solvents were the only reagents employed, the alcohol concentrations used in these procedures nevertheless give rise to significant disposal and safety concerns especially when high volumes of samples are processed.

With the advent of nucleic acid amplification reactions such as, for example, the polymerase chain reaction (PCR), the ligase chain reaction (LCR), and other similar procedures designed to synthesize multiple copies of a target nucleic acid sequence, isolating nucleic acid sequences from source materials (variously referred to as "sample

preparation” or “sample prep”) has become an increasingly important research area.

Several considerations, outside of the mere purification of nucleic acid sequences, make discovery of useful sample prep methods challenging. For example, sample-to-sample contamination with extraneous nucleic acid is a well documented and significant concern.

5 Additionally, initial samples that contain the desired nucleic acid sequence (or “target nucleic acid sequence”), often times contain very small concentrations of the target sequence, as well as comparatively large concentrations of extraneous nucleic acid.

Moreover, sample prep often times is performed in areas that are highly regulated in terms of the reagents that can be used and ultimately discarded. Further, in instances where the
10 nucleic acid is being purified for purposes of use in an amplification reaction, it is important for the nucleic acid to ultimately reside in a buffer that does not comprise components that inhibit enzymes commonly employed in amplification reactions. Hence, several considerations, beyond the mere purification of nucleic acid sequences, must be accounted for in the design of a useful sample prep method.

15 Thus, there is a need for a sample prep method that provides for quantitative isolation of nucleic acid with minimal handling and does not need flammable organic solvents.

Summary of the Invention

20 The present invention provides a method for separating nucleic acid from a test sample comprising the steps of contacting a test sample with a metal oxide support material and a binding buffer to form nucleic acid/metal oxide support material complexes, separating the complexes from the test sample; and eluting the nucleic acid from the metal oxide support material. The binding buffer generally will comprise a
25 chaotropic agent and a detergent, but may also comprise organic solvents and reducing agents. Preferably the binding buffer will have a flash point of greater than 125 degrees Fahrenheit. The method is sufficiently robust that it can purify nucleic acid from distinct nucleic acid containing sources such as bacteria and virus such that it later can be detected.

Brief Description of the Drawings

Figure 1 and Figure 2 represent computer analysis of data obtained in the Examples.

Detailed Description of the Invention

The methods provided herein employ a metal oxide support material to separate nucleic acid from other, but not necessarily all, components found in a test sample. Specifically, the metal oxide is employed to purify nucleic acid from other components in a test sample. It has been discovered that using metal oxide support materials as taught herein provides several important advantages over currently available sample preparation methods. For example, metal oxides have a high affinity for nucleic acid sequences and therefore sample-to-sample contamination is minimized because nucleic acid can controllably be bound to the metal oxide support without escaping to undesired areas. Additionally, metal oxide supports provide for a more quantitative purification of nucleic acid in a test sample and therefore even small amounts of a desired nucleic acid that may be present in the test sample are collected. Moreover, metal oxide particles can be employed to separate nucleic acid from a test sample with low organic-solvent concentrations (or, significantly, without the use of organic solvents) such as alcohol, phenol or chloroform, which are commonly employed according to other sample prep methods, but pose significant disposal concerns. Further, nucleic acid can be eluted from metal oxide supports using buffers that are completely compatible with amplification reactions. In other words, nucleic acid separated from a test sample in the manner provided herein directly can be employed in an amplification reaction without the need to exchange the elution buffer with a buffer compatible with an amplification reaction.

Additionally, the method provided herein can be employed to separate both DNA and the various forms of RNA from a single test sample. Hence, the method provided herein can be employed to separate nucleic acid from various different cells and/or organisms in the same test sample such that it later can be detected.

Generally, the method comprises contacting a test sample with a metal oxide support material and a binding buffer. In the presence of binding buffer, nucleic acid of

all types, such as DNA and the various forms of RNA, contained in the test sample binds the metal oxide support material. The metal oxide support material and any nucleic acid bound thereto then can be separated from the test sample. If desired, the support material, and any bound nucleic acid, can be washed before the nucleic acid is eluted using an elution buffer. Any eluted nucleic acid can then be detected using any of a variety of well known detection techniques.

The term "test sample" as used herein means anything suspected of containing a nucleic acid. The test sample is, or can be derived from, any source such as, for example, biological sources including blood, ocular lens fluid, cerebral spinal fluid, milk, ascites fluid, synovial fluid, peritoneal fluid, amniotic fluid, tissue, fermentation broths, cell cultures, products of an amplification reaction, nucleic acid synthesis products and the like. Test samples can also be from, for example, environmental or forensic sources including sewage or cloth. The test sample can be used directly as obtained from the source or following a pre-treatment to modify the character of the sample. Thus, the test sample can be pre-treated prior to use by, for example, preparing plasma from blood, isolating cells from biological fluids, homogenizing tissue, disrupting cells or viral particles, preparing liquids from solid materials, diluting viscous fluids, filtering liquids, distilling liquids, concentrating liquids, inactivating interfering components, adding reagents, purifying nucleic acids, and the like.

"Metal oxide support materials" as used herein means oxides and hydroxides of metallic elements in any of their various valence states. Thus, for example, oxides of aluminum, magnesium, titanium, zirconium, iron, silicon, nickel, chromium, zinc and combinations of the foregoing are metal oxide support materials. Iron oxides are preferred metal oxide support materials. Ferrous oxide (Fe_3O_4) and ferric oxide (Fe_2O_3) are therefore preferable metal oxide support materials. Metal oxide support materials can be in any configuration such as, for example, plates, particles, coatings, fibers, porous structures such as filters. Due to their high surface area, particles are the preferred configuration of the metal oxide support material.

"Binding buffers" facilitate binding of nucleic acid present in a test sample to metal oxide support materials. It has been found that nucleic acid will bind to metal oxide support materials in an extensive variety of buffers without regard to the pH of the buffer.

Hence, the binding buffer can have an acidic pH (less than 7), neutral pH (equal to 7), or a basic pH (greater than 7). Binding buffers will generally comprise a buffering system. Buffering systems are well known and a matter of choice for those skilled in the art. Buffering systems are typically an aqueous solution of a weak acid and its corresponding base, such as, for example, sodium phosphate and phosphoric acid. Preferably, binding buffers have a pH of between 3 and 12, more preferably between 3 and 11, and most preferably between 4 and 10. The binding buffers may also contain detergents well known to those skilled in the art such as non-ionic detergents, ionic detergents, zwitterionic detergents, at a total concentration of between 1% and 25% and preferably between 5% and 20%.

In cases where nucleic acid is purified directly from, for example cells or virus particles which contain nucleic acid, the binding buffer preferably further comprises a chaotropic agent at a concentration of between 2M and 10M, preferably between 3M and 6M. Chaotropic agents are well known in the art and include entities that break down, or solubilize, proteins. Exemplary chaotropic reagents include, but are not limited to guanidine isothiocyanate (GITC), guanidine HCl, potassium iodide, urea and the like. Reducing agents such as mercaptoethanol, dithiothreitol, and 2-mercaptoethanesulfonic acid can also be added to the binding buffer at concentrations between 25mM and 150 mM, and preferably 50 mM to 100 mM.

Although it is not necessary, the binding buffer may also include an alcohol, or other organic solvent, at concentrations that do not result in a binding buffer having a flash point greater than 125° Fahrenheit. The flashpoint of the buffer can be determined using any of the well known methods for determining the flash point of a liquid. Generally, organic solvents employed at concentrations of less than 15% will result in a binding buffer having a flash point of greater than 125° Fahrenheit. Lower alcohols such as methanol, ethanol, propanol and isopropanol are preferred alcohols in cases where a solvent is added to the binding buffer.

As mentioned previously, in the presence of the binding buffer, nucleic acid in the test sample will bind the support material. Upon formation of the complexes between the nucleic acid and support material, the support material can be separated from the binding buffer and remaining test sample. Depending upon the configuration of the support

material, the method of separation will be a matter of choice for one skilled in the art. For example, if the support material is in a particulate form, the support material can be, for example, sedimented and the remaining liquid material can be removed from the support through aspiration or simply pouring the liquid off of the support material. Given the composition of the support materials according to the present invention, it is preferable to use a magnetic field to facilitate sedimentation or isolation of particulate support materials.

Nucleic acid sequences complexed to the support material, if desired, can be washed with any buffer that does not dissociate the nucleic acid from the support material. Wash buffers typically are employed to cleanse the support material, and any nucleic acid complexed thereto, of any residual and undesired test sample components. Such wash buffers are well known in the art and typically contain solutions of detergents such as those previously mentioned in similar concentrations. Such detergents are typically diluted in buffering systems, also defined above.

Whether or not washed, nucleic acid complexed to the support material may be removed or dissociated from the metal oxide support material using water or an elution buffer. An "elution buffer" according to the present invention can be any reagent or set of reagents that separates bound nucleic acid from the metal oxide support material. Preferably, such a reagent will be compatible with detection system employed for the nucleic acid, and particularly compatible with reagents employed in nucleic acid amplification systems. Water, that may be distilled, deionized, or otherwise purified, may serve as an elution buffer for purposes of the present invention. Elution buffers (typically comprising a buffering system as described above) containing phosphate, or bicine also have been found to be suitable elution buffers and others can easily be found empirically using ordinary skill in the art such as by contacting metal oxide-nucleic acid complexes with a buffer and determining if separation has occurred (as exemplified below). The elution buffer may contain inorganic or organic phosphate through addition of sodium phosphate or organophosphate compounds which are organic compounds containing at least one phosphate functionality at concentrations of between 10mM to 300mM, preferably between 10mM and 100mM. O-phosphoserine, phosphoethanolamine, carbamyl phosphate, phosphocreatine, adenosine monophosphate (AMP), and

phosphotungstic acid are examples of organophosphate compounds. Suitable pH's for elution buffers can be between 6 and 10, and preferably between 7 and 9.

Purified nucleic acid then can be detected using assays well known in the art. For example, sandwich hybridization assays can be employed with or without an amplification
5 step prior to detection. Well known amplification reactions such as, for example, TMA, QB-replicase, NASBA, SDA, LCR, and PCR are examples of amplification reactions that can be employed to amplify nucleic acid purified according to the present invention.

The above amplification reactions typically employ names amplification reagents. The phrase "amplification reaction reagents" as used herein means reagents which are well
10 known for their use in nucleic acid amplification reactions and may include but are not limited to: primers, probes, a single or multiple reagent, reagents, enzyme or enzymes separately or individually having reverse transcriptase, polymerase, and/or ligase activity; enzyme cofactors such as magnesium or manganese; salts; nicotinamide adenine dinucleotide (NAD); and deoxynucleoside triphosphates (dNTPs) such as, for example,
15 deoxyadenosine triphosphate, deoxyguanosine triphosphate, deoxycytidine triphosphate and thymidine triphosphate. The exact amplification reagents employed are largely a matter of choice for one skilled in the art based upon the particular amplification reaction employed.

It was discovered that amplification of nucleic acid, as purified above, can be
20 performed in the elution buffer employed to dissociate the nucleic acid from the metal oxide support material. In particular, amplification reagents can be combined with the nucleic acid in the elution buffer and amplification of the nucleic acid can directly be performed.

The present invention further provides kits comprising suitably packaged reagents
25 for isolating nucleic acid according to the present invention. The kits may include a metal oxide support material, a binding buffer (as described above), and an elution buffer (as described above). The kit may also contain other suitably packaged reagents and materials for using the isolated nucleic acid in a particular assay. By way of example, the kit may further include, nucleic acid amplification primers and/or nucleic acid probes,
30 buffers, nucleotides, enzymes, conjugates, and the like.

The Examples that follow illustrate preferred embodiments of the present invention and are not limiting of the claims and specification in any way.

Examples

Example 1

Binding and Elution of Radio-Labeled RNA Using Metal Oxide Support Materials

In this example, radio-labeled RNA was bound to various metal oxide support materials, washed, and then eluted from the support materials. The counts per minute (CPM) were monitored throughout the course of the process to determine the amount of bound RNA as well as the amount of RNA lost during the wash, and finally, the amount of the RNA eluted.

The radio-labeled RNA employed in this experiment was generated using the Riboprobe T7 RNA polymerase transcription system and pGEMEX-1 positive control template from Promega Corporation. In the binding and elution experiment, approximately 8,000,000 CPM of the radio-labeled probe was added to suspensions of 5 mg Fe_3O_4 or Fe_2O_3 metal oxide particles (obtained from ISK Magnetics; Valparaiso, IN) in 6 ml of a guanidine isothiocyanate-detergent solution (6M GITC, 10% Tween-20, 16 mM cetyltrimethylammonium bromide, 100 mM sodium acetate, 100 mM Dithiothreitol, pH 4.2, 7.5% ethanol). After adding the RNA to the respective particle suspensions, the suspensions were briefly vortexed and incubated at 37°C for 30 minutes.

After the incubation, the metal oxide particles were pulled to the sides of the respective microfuge tubes with a magnet and the supernatants were aspirated with a pipette. The CPM of the supernatants were determined and are recorded in Table 1, below, as "Unbound" RNA.

The particles were then washed by adding 0.5 ml of a wash solution and vortexing the newly formed suspension before pulling the particles to the side of the microfuge tube as above and aspirating the wash solution from the microfuge tube. The particles were washed twice with a guanidinium isothiocyanate-detergent solution (2M GITC, 5% Tween-20, 50 mM KOAc, pH 6) and twice with 50 mM Tris buffer, pH 8.0. The washes were pooled and the amount of label removed from the particles was determined and is recorded in Table 1 as "Wash".

After the wash solution was aspirated, 200 microliters of elution buffer was added to the tubes containing the washed particles. The elution buffer was a solution of 100 mM o-phosphoserine (Sigma Chemical Co., St. Louis, MO) and 300 mM Tris base with a final pH of 8.0. After addition of the elution buffer, the newly formed particle suspensions were briefly vortexed and the suspension was incubated at 70°C for 30 minutes. After incubation the particles were captured on the sides of the tubes using a magnetic rack and the eluant removed. The CPM were determined and is recorded in Table 1 as "Eluant 1". Fresh elution buffer was added to the particles and the elution process was repeated and the CPM of the second elution is recorded in Table 1 as "Eluant 2".

The particles were resuspended in a third 200 microliter aliquot of elution buffer and a sample containing elution buffer and resuspended particles was used to determine the amount of probe which was not released from the particles. This is recorded in Table 1 as "Bound".

All values shown in Table 1 are recorded as a percent of the total CPM.

Table 1
% Total CPM

Particles	Unbound	Wash	Eluant 1	Eluant 2	Bound
Fe ₃ O ₄	10	2	70	15	3
Fe ₂ O ₃	7	2	63	10	18

As shown by the data in Table 1, the ferric oxide and ferrous oxide particles bound RNA and the RNA was eluted from the respective particles with the phosphate buffer.

Example 2

Elution of RNA from Fe₃O₄ Using Various Phosphate Concentrations

In this example, radio-labeled RNA prepared as in Example 1 was bound to Fe₂O₃ magnetic particles, washed, and eluted with various concentrations of sodium phosphate (Na₂HPO₄) buffer. The elution buffer concentrations ranged from 10 to 50 mM Na₂HPO₄ (pH 9). Approximately 23,000,000 CPM of the radio-labeled nucleic acid was added to a suspension of 25 mg Fe₂O₃ metal oxide particles (0.25 ml of a 10% w/vol suspension of

particles in water) in 30 ml of a guanidine isothiocyanate-detergent solution (4M GITC, 10% Tween-20, 16 mM cetyltrimethylammonium bromide, 100 mM 2-mercaptoethanesulfonic acid, 100 mM potassium acetate, pH 6) . 5 ml of water was then added to the suspension to simulate the dilution effect of five 1 ml samples. The suspension was briefly vortexed and was divided into 5 equal aliquots of 7 ml each and all of the suspensions were incubated at 37°C for 20 minutes.

After the incubation, the metal oxide particles were pulled to the sides of the respective microfuge tubes with a magnet and the supernatants were aspirated with a pipette. The amount of unbound probe was monitored with a Geiger counter and very low amounts of radio-labeled nucleic acid were not captured when compared to the amount of radioactivity bound to the particles monitored in an identical fashion. The exact CPM of the unbound material was not determined.

The particles were then washed by adding 0.5 ml of a wash solution and vortexing the newly formed suspension before pulling the particles to the side of the microfuge tube as above and aspirating the wash solution from the microfuge tube. The particles were washed twice with (2M GITC, 5% Tween-20, 50 mM KOAc, pH 6) and twice with (50 mM Tris buffer , pH 8.0). The washes were monitored with a Geiger counter and the amount of radioactivity released during the wash procedure was also found to be negligible. The samples were eluted with 0.2 ml of each of the elution buffers at 73°C for 10 minutes. The eluant was collected after magnetic capture of the particles and saved. The elution protocol was repeated and the second eluant was also saved. A third aliquot of elution buffer was also added to the particles and the particles in suspension were used to determine the amount of bound probe. 20 µl aliquots of each of the eluants and particle suspensions were mixed with 5 ml of scintillation fluor and counted. Table 2 reports the concentrations of sodium phosphate in the elution buffers employed in this experiment (column 1), the percentage of the total counts recovered after a first and second elution (columns 2 and 3), and the percentage of the counts remaining on the magnetic particles after both elutions ("Bound").

Table 2

Elution Buffer	Elution 1	Elution 2	Bound
10 mM Na ₂ HPO ₄	45	20	35
20 mM Na ₂ HPO ₄	68	18	14
30 mM Na ₂ HPO ₄	75	16	9
40 mM Na ₂ HPO ₄	76	16	8
50 mM Na ₂ HPO ₄	79	14	7

As shown by Table 2, various concentrations of phosphate buffer eluted the RNA from the metal oxide particles.

5

Example 3

Use of Organophosphate Elution Buffers

In this example, various organophosphate buffers were tested for their ability to elute nucleic acid from a metal oxide support material compared to inorganic phosphate buffers. All of the organophosphate compounds employed in the elution buffers were obtained from Sigma Chemical Co. Except where indicated in Table 3, all buffers were made at 50 mM and pHed with 1 M tris base to a final pH of between 6.5 and 9. As in the previous examples, the radio-labeled RNA was made as in Example 1. Approximately 1,000,000 CPM of the radio-labeled RNA was added to a suspension of 10 mg Fe₂O₃ metal oxide particles in 12 ml of a guanidine isothiocyanate-detergent solution (6M GITC, 10% Tween-20, 16 mM cetyltrimethylammonium bromide, 100 mM sodium acetate, 100 mM Dithiothreitol, pH 4.2, 7.5% ethanol). 2 ml of water was added to the suspension to simulate the addition of sample. The suspension was briefly vortexed and incubated at 37°C for 25 minutes. The particles were collected magnetically and the supernatant removed. No significant loss of signal was observed in the supernatant when checked by Geiger counter. The particles were washed by resuspending the particles in 6 ml of 50 mM potassium acetate, pH 6.0. The particles were collected magnetically and the wash fluid was removed. No significant loss of signal was observed in the supernatant when checked by Geiger counter. The wash procedure was repeated. The particles were then resuspended in 6 ml of the potassium acetate wash fluid, mixed well, and 0.5 ml aliquots

10

15

20

25

were dispensed into 10 separate 1.5 ml microfuge tubes. The tubes were transferred to a magnetic rack, the particles collected on the sides of the tubes, and the wash fluid was removed. 100 microliters of various elution buffers were then added to the microparticles and incubated at 70°C for 10 minutes. 50 microliters of the eluted samples was then counted in a scintillation counter to determine the amount of released probe. The approximate total counts of starting material (nucleic acid) was 40,000 CPM/sample. Table 3 gives the results of this experiment and reports the elution buffer and the counts released with that elution buffer.

Table 3

Elution Buffer	Released Counts
Adenosine monophosphate (pH 6.5)	17,229
Phosphocreatine (pH 7)	9172
O-phosphoryethanolamine (pH 7)	3379
Carbamyl phosphate (pH 7)	27,717
Phosphonoacetic acid (pH8)	29,367
Phosphorylcholine (pH 7)	404
Phosphotungstic acid (pH 8)	34,825
O-phospho-dl-serine (pH 7)	18,807
30 mM Na ₂ HPO ₄ (pH 8)	29,277
30 mM Na ₂ HPO ₄ (pH 9)	20,468

As shown by Table 3, organophosphate buffers are suitable buffers for eluting bound nucleic acid from metal oxide support materials.

Example 4

Extraction of RNA from HIV Virions in Plasma

In this example, HIV nucleic acid was extracted from four test panels of plasma that contained various levels of the HIV virions using the metal oxide particles described

above. Negative plasma was used as a negative control. Nucleic acid from the plasma samples was also extracted using the commercially available Qiagen viral nucleic acid extraction kit (Qiagen Inc.; Valencia CA). The HIV nucleic acid in the samples was analysed using the Abbott LCx® Quantitative HIV assay (available from Abbott Laboratories; Abbott Park, IL).

The respective sample preparation procedures were performed on 1 ml of plasma samples from each of the four test panels and the negative control. The Qiagen procedure was performed on the panels in accordance with the manufacturer's instructions and the samples quantitated using the Abbott LCx® HIV assay. Test panels 1-4 contained 28 virions/ml, 110 virions/ml, 800 virions/ml and 10,000 virions/ml respectively. The metal oxide procedure was performed by mixing 1 ml of test plasma sample with 6 ml of binding buffer (5M guanidinium isothiocyanate, 10% Tween-20, 16 mM cetyltrimethylammonium bromide, 100 mM dithiothreitol, 100 mM Na acetate, pH 4.1) and 5 mg of Fe₂O₃ particles. The lysate was incubated at 37°C for 20 minutes. The particles were then washed by adding 0.5 ml of a wash solution and vortexing the newly formed suspension before pulling the particles to the side of the microfuge tube as above and aspirating the wash solution from the microfuge tube. The particles were washed twice with 2M GITC, 5% Tween-20, 50 mM KOAc, pH 6, and twice with 50 mM Tris buffer, pH 8.0. After the wash solution was aspirated, 200 microliters of elution buffer was added to the tubes containing the washed particles. The elution buffer was a solution of 50 mM o-phosphoserine and 150 mM Tris base with a final pH of 8.0. After addition of the elution buffer, the newly formed particle suspensions were briefly vortexed and the suspension was incubated at 70°C for 30 minutes. After incubation the particles were captured on the sides of the tubes using a magnetic rack and the eluant removed. 50 µl of the solutions recovered according to the respective sample prep procedures were then subject to amplification and detection.

50 µl aliquots from the respective sample prep methods were reverse transcribed and amplified using PCR. RT-PCR was performed using 1X EZ Buffer, 2.5 mM manganese chloride, dNTPs (dATP, dGTP, dTTP and dCTP) present at a final concentration of 0.15 mM each, and recombinant *Thermus thermophilus* polymerase at a

concentration of 5 units/reaction. The labeled primer was used at a concentration of 40 nM and the unlabeled primer concentration was used at a concentration of 40 nM. The probe, which was labeled as specified above and that ultimately hybridizes with the product of the labeled primer prior to detection of the resultant hybrid complex, was used at a concentration of 10 nM.

Reaction mixtures were reverse transcribed and amplified in a Perkin-Elmer 480 Thermal Cycler. Reaction mixtures were first incubated at 62°C for 30 minutes to reverse transcribe the RNA, followed by 2 minutes at 94°C. PCR amplification was then initiated through a touchdown or step-down protocol to aid in the stringency of the reaction in the early stages of amplification. This utilized 8 cycles as follows: 1 cycle at 94°C for 30 seconds then 70°C for 80 seconds followed by 1 cycle of 94°C for 30 seconds then 69°C for 80 seconds, followed by 1 cycle of 94°C for 30 seconds then 68°C for 80 seconds, followed by 1 cycle of 94°C for 30 seconds then 67°C for 80 seconds, followed by 1 cycle of 94°C for 30 seconds then 66°C for 80 seconds, followed by 1 cycle of 94°C for 30 seconds then 65°C for 80 seconds, followed by 1 cycle of 94°C for 30 seconds then 64°C for 80 seconds, followed by 1 cycle of 94°C for 30 seconds then 63°C for 80 seconds. Further amplification was then accomplished with 35 cycles at 94°C for 30 seconds then 62°C for 80 seconds. After the reaction mixtures were thermal cycled, all duplicates were pooled and mixed by pipetting to eliminate any variation due to cycling. The mixtures were then split and denatured for 5 minutes at 97°C. Following this, probe oligo hybridization was accomplished by lowering the temperature to 15°C for 5 minutes. The temperature was then lowered to 4°C and samples were held at 4°C until the reaction products were detected.

The results obtained for the four test panels and negative control are shown in Table 4 below as copies/ml.

Table 4

Sample Prep Method	Negative Control	Panel 1	Panel 2	Panel 3	Panel 4
Qiagen	5	75	90	900	9000
Metal Oxide	9	80	100	850	10,000

As shown in the results from Table 4 the metal oxide sample prep procedure successfully extracted nucleic acid from plasma in amounts sufficient for amplification and detection.

Example 5

Extraction of nucleic acids from HIV and HBV Virions in Plasma

In this example, HIV nucleic acid (RNA) and HBV nucleic acid (DNA) was extracted from one ml of plasma that contained both HIV and HBV virions each at a concentration of 1000 virions/ml using the metal oxide particles described above. Negative plasma was used as a negative control. The lysis conditions were varied to cover a range of concentrations of GITC (3.33 to 4.66M), DTT (0 to 100mM), Tween-20 (13.3 to 24%), and CTAB(0 to 24 mM) as well as pH(4 to 10), and temperature(35°C to 55°C). 45 different combinations of reagents and conditions were used in the lysis step with all samples being extracted with 3 ml of lysis buffer. 5 mg of Fe₂O₃ particles were used in each extraction. Each condition was used at least three times with the centerpoint conditions being used 30 times. The particles were washed twice with 2M GITC, 5% Tween-20, 50 mM KOAc, pH 6 and twice with 50 mM Tris buffer , pH 8.0. After the wash solution was aspirated, 200 microliters of elution buffer was added to the tubes containing the washed particles. The elution buffer was a solution of 50 mM o-phosphoserine and 150 mM Tris base with a final pH of 8.0. After addition of the elution buffer, the newly formed particle suspensions were briefly vortexed and the suspension was incubated at 70°C for 30 minutes. After incubation the particles were captured on the sides of the tubes using a magnetic rack and the eluant removed. 50 µl of the solutions recovered according to the respective sample prep procedures were then subject to

amplification and detection. The eluted material was split and analyzed using two PCR based assays, one for HIV and one for HBV. The assays are "beacon" assays and utilize a hybridization probe which has an increase in fluorescence upon the binding of the probe to amplified target material.

5 For the HIV assays, 50 µl aliquots from the respective sample prep methods were reverse transcribed and amplified using PCR. RT-PCR was performed using 1X EZ Buffer, 3 mM manganese chloride, dNTPs (dATP, dGTP, dTTP and dCTP) present at a final concentration of 0.100 mM each, and recombinant *Thermus thermophilus* polymerase at a concentration of 14.4 units/reaction. The forward primer (SEQ ID NO 1) was used at a concentration of 188 nM and the reverse primer (SEQ ID NO 2) was used at
10 a concentration of 469nM. The HIV beacon probe (SEQ ID NO 3) was used at a concentration of 100 nM. Reaction mixtures were reverse transcribed and amplified in a Perkin-Elmer 9700 Thermal Cycler using 96 well amplification trays. Reaction mixtures were first incubated at 59°C for 30 minutes to reverse transcribe the RNA. PCR
15 amplification was then accomplished with 5 cycles at 92°C for 15 seconds then 59°C for 30 seconds and then 72°C for 15 seconds. This was followed by 55 cycles at 92°C for 4 seconds then 64°C for 8 seconds and then 72°C for 4 seconds. The reactions were then heated to 92°C for 30 seconds and then held at 45°C for 15 minutes and then lowered to 25°C. The amount of signal was determined by reading the plate in a Cytofluor Series
20 4000 plate reader.

For the HBV assays, 50 µl aliquots from the respective sample prep methods were amplified using PCR. PCR was performed using 1X PCR Buffer, 3.5 mM magnesium chloride, dNTPs (dATP, dGTP, dTTP and dCTP) present at a final concentration of 0.100 mM each, and AmpliTaq Gold at a concentration of 7 units/reaction. The forward primer
25 (SEQ ID NO 4) was used at a concentration of 200 nM and the reverse primer (SEQ ID NO 5) was used at a concentration of 300nM. The HBV beacon probe (SEQ ID NO 6) was used at a concentration of 50 nM. Reaction mixtures were amplified in a Perkin-Elmer 9700 Thermal Cycler using 96 well amplification trays. Reaction mixtures were first incubated at 94°C for 10 minutes to activate the enzyme. PCR amplification was then
30 accomplished with 45 cycles at 94°C for 60 seconds then 58°C for 30 seconds. The reactions were then kept at 58°C for 10 minutes, the temperature raised to 94°C for 5

minutes and then held at 55°C for 15 minutes and then lowered to 25°C. The amount of signal was determined by reading the plate in a Cytofluor Series 4000 plate reader.

The signals generated from the various samples in the study are represented in Table 5 for the HIV samples and Table 6 for the HBV samples. The tables show the lysis conditions used for the samples and the signals generated for the internal control which was processed with the samples and either the HIV or the HBV signals from the samples. The ratios of the signals from the positive samples to the signals from the negative samples were plotted and analyzed using JMP software from SAS Institute Inc. The results from both the HIV and HBV extractions, Figures 1 and 2 respectively, show that a wide range of conditions can be used in the process for both HIV and HBV and that many conditions allow for the simultaneous extraction of both HIV and HBV.

Table 5

Pattern	mM CTAB	mM DTT	pH	% Tween-20	M GITC	Temp	Neg Fam (HIV)	Neg TR (int Ctrl)	Pos Fam (HIV)	Pos TR(int Ctrl)
-----	0	0	4	13.3	3.33	35	5486.333	3692	11262	8526.333
----++	0	0	4	13.3	4.66	55	4424.667	9302	11482	7854.333
---+++	0	0	4	24	3.33	55	5666	4089.333	7072.333	5088.333
---++-	0	0	4	24	4.66	35	5015.667	12252.33	19858.67	11733
--+++	0	0	10	13.3	3.33	55	4879.333	13952	21567	12767
--++-	0	0	10	13.3	4.66	35	4479.333	14033.33	23514.67	12948
-+++	0	0	10	24	3.33	35	4977	9272	14768	7690
-++-	0	0	10	24	4.66	55	4806.333	10057.33	15730.33	8273.667
-+++	0	100	4	13.3	3.33	55	5393	6056.333	9859.333	6102.333
-++-	0	100	4	13.3	4.66	35	5483.667	11603.67	14634.67	9215
-+-+	0	100	4	24	3.33	35	5834	6525.667	8937	5768.667
-+--	0	100	4	24	4.66	55	5011.333	8967.333	11264	8388
-+++	0	100	10	13.3	3.33	35	4099	8307.333	11902.33	7301.333
-++-	0	100	10	13.3	4.66	55	4374.667	3469.333	5251.333	3742.667
-+-+	0	100	10	24	3.33	55	4273.667	5029	7707	4766
-+--	0	100	10	24	4.66	35	4448.333	10494	19596.33	10200.67
++++	24	0	4	13.3	3.33	55	5432	8296	14120	9926.333
+++	24	0	4	13.3	4.66	35	4669.333	13721.67	15696	12326
++	24	0	4	24	3.33	35	5425.667	5036	12432.67	7527
+	24	0	4	24	4.66	55	4964.667	10306.33	14561	9487
-	24	0	10	13.3	3.33	35	4827.333	15834	15675.33	12000
---	24	0	10	13.3	4.66	55	4698.333	9623.667	15484.67	7829
----	24	0	10	24	3.33	55	4667	10944.33	12604	6841
-----	24	0	10	24	4.66	35	4761.333	11392.33	18971.67	9964.333
++++	24	100	4	13.3	3.33	35	5615	5676.333	12048.67	8041.667
+++	24	100	4	13.3	4.66	55	4729.333	6406	10190.67	6842
++	24	100	4	24	3.33	55	4918	4094	5869.667	4057.333
+	24	100	4	24	4.66	35	5823	12712.33	17049.67	9150
-	24	100	10	13.3	3.33	55	4287	4109	6732.333	4039
---	24	100	10	13.3	4.66	35	4724.667	6374	11157.33	5757
----	24	100	10	24	3.33	35	4672.333	9511.333	15455	7734
-----	24	100	10	24	4.66	55	3979.333	3732	5256.667	3812
000000	12	50	7	18.65	3.995	45	4850.833	13233.87	21264.6	11335.3
-00000	0	50	7	18.65	3.995	45	4921	14609.67	27921.67	11625.67
+00000	24	50	7	18.65	3.995	45	4405.667	14558.33	25260	11686
0-0000	12	0	7	18.65	3.995	45	4490.333	13230.33	24602.33	11658
0+0000	12	100	7	18.65	3.995	45	4585.667	10166	19681.33	8925.333
00-000	12	50	4	18.65	3.995	45	5469.667	9663.333	15432.33	7177.667
00+000	12	50	10	18.65	3.995	45	4450.667	8384.333	16545.67	5780.667
000-00	12	50	7	13.3	3.995	45	4665	10743	21749	10346.33
000+00	12	50	7	24	3.995	45	4551	10010.33	21181.33	8998.667
0000-0	12	50	7	18.65	3.33	45	4614.667	10809.67	23293.33	11219
0000+0	12	50	7	18.65	4.66	45	4811.333	13213	22731.67	10757.33
00000-	12	50	7	18.65	3.995	35	5195	12653	21010.33	8770.667
00000+	12	50	7	18.65	3.995	55	4798.667	11609	20922	8777.333

Table 6

Pattern	mM CTAB	mM DTT	pH	% Tween-20	M GTC	Temp	Neg Fam (HBV)	Neg TR (int Ctrl)	Pos Fam (HBV)	Pos TR(int Ctrl)
-----	0	0	4	13.3	3.33	35	13763	15857	19806	18835
----++	0	0	4	13.3	4.66	55	12691	16123	24121	16359
---+++	0	0	4	24	3.33	55	16384	20296	20057	18493
---+-	0	0	4	24	4.66	35	13143	19228	17052	21522
--++-	0	0	10	13.3	3.33	55	16249	20133	22242	22616
--+-+	0	0	10	13.3	4.66	35	13593	24713	19682	26061
---+-	0	0	10	24	3.33	35	14912	19756	19189	22207
----++	0	0	10	24	4.66	55	15950	27230	18497	24681
-+---+	0	100	4	13.3	3.33	55	15319	23021	27155	19706
-+--+-	0	100	4	13.3	4.66	35	16135	24778	26854	20820
-++---	0	100	4	24	3.33	35	17592	21386	27391	20735
-++---+	0	100	4	24	4.66	55	14416	22597	27652	17980
++---	0	100	10	13.3	3.33	35	12321	17029	27663	18062
++---+	0	100	10	13.3	4.66	55	12937	24453	32857	19601
+++--	0	100	10	24	3.33	55	13406	23679	28120	19813
+++--+	0	100	10	24	4.66	35	14247	23632	29093	19725
+----+	24	0	4	13.3	3.33	55	14825	22245	27359	21866
+---+-	24	0	4	13.3	4.66	35	14557	20537	19770	19482
+--+-	24	0	4	24	3.33	35	16013	19770	18575	14349
+--++	24	0	4	24	4.66	55	14816	21794	24068	18830
+-+--	24	0	10	13.3	3.33	35	14828	13285	16079	9985
+-+--+	24	0	10	13.3	4.66	55	14470	19531	16739	21070
+---+-	24	0	10	24	3.33	55	15201	23681	14966	18047
+---++	24	0	10	24	4.66	35	15645	18663	17625	21305
++---	24	100	4	13.3	3.33	35	14931	21110	27690	20362
++---+	24	100	4	13.3	4.66	55	13502	17549	29140	16016
+++--	24	100	4	24	3.33	55	13904	20313	24367	14119
+++--+	24	100	4	24	4.66	35	15840	26220	29686	21216
+++--	24	100	10	13.3	3.33	55	14098	20319	26624	16095
+++--+	24	100	10	13.3	4.66	35	15464	27136	34458	17911
++++--	24	100	10	24	3.33	35	15052	24848	29940	20050
++++++	24	100	10	24	4.66	55	13094	19608	25388	14897
000000	12	50	7	18.65	3.995	45	14548	23128	24077	19954
-00000	0	50	7	18.65	3.995	45	13771	24107	18997	24754
+00000	24	50	7	18.65	3.995	45	12406	23835	17921	21838
0-0000	12	0	7	18.65	3.995	45	12699	23712	19340	24507
0+0000	12	100	7	18.65	3.995	45	13936	25988	26736	19736
00-000	12	50	4	18.65	3.995	45	14715	26245	27755	18442
00+000	12	50	10	18.65	3.995	45	13446	25754	26293	18507
000-00	12	50	7	13.3	3.995	45	12827	23411	23485	18005
000+00	12	50	7	24	3.995	45	13103	23340	25270	20891
0000-0	12	50	7	18.65	3.33	45	13992	24536	24898	21251
0000+0	12	50	7	18.65	4.66	45	14545	25227	25865	21429
00000-	12	50	7	18.65	3.995	35	15186	25297	23463	19417
00000+	12	50	7	18.65	3.995	55	15190	27421	23149	20780

Example 6

Extraction of nucleic acids from

Chlamydia trachomatis and *Neisseria gonorrhoeae* in urine.

In this example, nucleic acids were extracted from one ml of urine that contained both *Chlamydia trachomatis* and *Neisseria gonorrhoeae* using the metal oxide method described above. Nucleic acids from the urine samples were also extracted using the LCx® Urine Specimen Preparation Kit. The extracted samples were tested for both *Chlamydia trachomatis* and *Neisseria gonorrhoeae* using LCx® assays from Abbott Laboratories.

The sample panels were made up using pooled urine that was tested to be negative for both *Chlamydia trachomatis* and *Neisseria gonorrhoeae* using ® assays from Abbott Laboratories. Positive urine panels were made by adding positive stocks of *C. trachomatis* and *N. gonorrhoeae* to the negative urine. The “low positive” panel contained 0.5 elementary bodies (EB) of *C. trachomatis* and 0.5 colony forming units (cfu) of *N. gonorrhoeae* per ml of urine. The “high positive” panel contained 10 EB of *C. trachomatis* and 10 cfu of *N. gonorrhoeae* per ml of urine.

The respective sample preparation procedures were performed on 1 ml of urine samples from each of the two test panels and the negative control. The metal oxide procedure was performed by mixing 1 ml of test urine sample with 3 ml of lysis buffer (4.3M guanidinium isothiocyanate, 18% Tween-20, 12 mM cetyltrimethylammonium bromide, 50 mM dithiothreitol, 100 mM Tris, pH 7.6) and 5 mg of Fe₂O₃ particles (M-2038, ISK Corporation). The extraction mix also contained 7.5 micrograms of polyA RNA as carrier. The lysate was incubated at 45°C for 20 minutes. The particles were captured magnetically and the lysate removed by aspiration. The particles were washed twice with a 2 M GITC, 5% tween-20, 50 mM K acetate pH 6.0, and twice with 50 mM Tris buffer, pH 8.0, 0.45% Na azide. After the wash solution was aspirated, 100 microliters of elution buffer was added to the tubes containing the washed particles. The elution buffer was water with 0.045% Na azide as a preservative. After addition of the elution buffer, the particles were resuspended by pipetting and the suspension was incubated at 70°C for 20 minutes. After incubation the particles were captured on the sides of the tubes using a magnetic rack and the eluant removed. The 100 microliters

recovered from the sample was then diluted with 900 microliters of LCx® Urine Specimen Resuspension Buffer (50 mM MgCl₂ and detergent). The resuspension buffer must be added to the extracted samples to add the MgCl₂ needed in the assay. 50 microliters of the sample was then used in the *Chlamydia trachomatis* and *Neisseria gonorrhoeae* LCx® assays from Abbott Laboratories.

The samples were also prepared using the LCx® Urine Sample Preparation Kit. 1 ml urine samples were centrifuged at 9,000 x g for 15 minutes and the supernatant was removed. 900 microliters of LCx® Urine Specimen Resuspension Buffer was added to the pellet and the sample vortexed to resuspend the sample. The sample was then heated at 97°C for 15 minutes to release the DNA. After cooling, 100 microliters of the elution buffer (water and 0.045% Na azide) used for the metal oxide process was added to the extracted samples to equilibrate the concentration of components to the metal oxide extracted samples. 50 microliters of the sample was then used in the *Chlamydia trachomatis* and *Neisseria gonorrhoeae* ® assays from Abbott Laboratories. Negative and positive controls were also run in the assays. The results for the *Chlamydia trachomatis* assays included a negative control which had a 0 rate signal and a positive control which had a rate signal of 1600. The remaining results for the *Chlamydia trachomatis* assays are shown in Table 7. The results for the *Neisseria gonorrhoeae* assays included a positive control which had a rate signal of 0 and a positive control which had a rate signal of 950. The remaining results for the *Neisseria gonorrhoeae* assays are shown in Table 8. The metal oxide process performed as well as the standard extraction method for the LCx® assays for both cell types.

Table 7

Assay Type & Sample Concentration	Rate
LCx® Negative Urine	0
LCx® Low Positive Urine	1000
LCx® High Positive Urine	1900
Fe ₂ O ₃ Negative Urine	0
Fe ₂ O ₃ Low Positive Urine	1400
Fe ₂ O ₃ High Positive Urine	1900

Table 8

Assay Type & Sample Concentration	Rate
LCx® Negative Urine	0
LCx® Low Positive Urine	450
LCx® High Positive Urine	1000
Fe ₂ O ₃ Negative Urine	0
Fe ₂ O ₃ Low Positive Urine	500
Fe ₂ O ₃ High Positive Urine	1000

Claims

What is claimed is:

1. A method for separating nucleic acid from a test sample comprising:
 - a) contacting a test sample with a metal oxide support material with a binding buffer to form nucleic acid/metal oxide support material complexes, wherein the binding buffer comprises a chaotropic agent and a detergent;
 - 5 b) separating the complexes from the test sample; and
 - c) eluting the nucleic acid from the metal oxide support material.
2. The method of claim 1 wherein the binding buffer further comprises a reducing agent.
3. The method of claim 1 wherein the binding buffer further comprises an organic solvent and the flashpoint of the binding buffer is greater than 130 degrees Fahrenheit.
4. The method of claim 2 wherein the binding buffer further comprises an organic solvent and the flashpoint of the binding buffer is greater than 130 degrees Fahrenheit.
5. The method of claim 1 further comprising a wash step after separating the complexes from the test sample and before eluting the nucleic acid from the metal oxide support material.
6. The method of claim 1 wherein eluting the nucleic acid from the metal oxide support material comprises contacting the complexes with a reagent selected from water or a phosphate containing buffer.
7. The method of claim 6 further comprising the step of detecting the nucleic acid after the eluting the nucleic acid from the metal oxide support material.

8. The method of claim 7 further comprising the step of amplifying the nucleic acid after eluting the nucleic acid from the metal oxide support material and before detecting the nucleic acid.
9. The method of claim 7 wherein the nucleic acid comprises nucleic acid from distinct sources.
10. The method of claim 9 wherein the nucleic acid is RNA and DNA.
11. A kit for separating nucleic acid from a test sample comprising:
 - a) metal oxide particles;
 - b) a binding buffer comprising
 - (i) a chaotropic reagent, and
 - (ii) a detergent; and
 - c) an elution buffer comprising water.




FIG.1A




FIG.1B

2/6




FIG.1C




FIG.1D




FIG.1E




FIG.1F

4/6




FIG.2A




FIG.2B

5/6




FIG.2C




FIG.2D

6/6




FIG.2E




FIG.2F

SEQUENCE LISTING

<110> Gundling, Gerard

<120> Nucleic Acid Isolation Method and Kit

<130> 6653.US.O1

<160> 6

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> HIV forward primer

<400> 1

attccctaca atccccaaag tcaaggagt 29

<210> 2

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> HIV reverse primer

<400> 2

cctgcactgt acccccctaat cc 22

<210> 3

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> HIV beacon probe

<400> 3

gcgagacagc agtacaaatg gcactcgc 28

<210> 4

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> HBV forward primer

<400> 4

tcttttcggag tgtggattcg cac 23

<210> 5

<211> 27

<212> DNA

<223> HBV reverse primer

<400> 5
ctaacattga gattcccgag attgaga 27

<210> 6
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> HBV beacon probe

<400> 6
ctcgctcccc tagaagaaga actccctcgg cgag 34

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/34997

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/10 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, CAB Data, STRAND, EPO-Internal, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 973 138 A (COLLIS MATTHEW P) 26 October 1999 (1999-10-26) the whole document ---	
A	EP 0 818 461 A (TOYO BOSEKI) 14 January 1998 (1998-01-14) the whole document ---	
A	WO 96 09379 A (WHITEHEAD BIOMEDICAL INST) 28 March 1996 (1996-03-28) the whole document ---	
A	DE 195 20 398 A (BOEHRINGER MANNHEIM GMBH) 12 December 1996 (1996-12-12) the whole document --- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

17 May 2001

Date of mailing of the international search report

23/05/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Hornig, H

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/34997

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95 33827 A (AMERSHAM INT PLC ;REEVE MICHAEL ALAN (GB); ROBINSON PHILIP STEVEN) 14 December 1995 (1995-12-14) the whole document ----	
A	WO 98 31840 A (PROMEGA CORP) 23 July 1998 (1998-07-23) the whole document ----	
A	WO 96 18731 A (DZIEGLEWSKA HANNA EVA ;DYNAL AS (NO); LARSEN FRANK (NO); DEGGERDAL) 20 June 1996 (1996-06-20) the whole document ----	
A	WO 91 12079 A (AMERSHAM INT PLC) 22 August 1991 (1991-08-22) the whole document -----	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/34997

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5973138 A	26-10-1999	AU 5707399 A EP 1002860 A JP 2000159791 A	01-06-2000 24-05-2000 13-06-2000
EP 0818461 A	14-01-1998	JP 3082908 B JP 10075784 A US 5990302 A	04-09-2000 24-03-1998 23-11-1999
WO 9609379 A	28-03-1996	US 5705628 A US 5898071 A	06-01-1998 27-04-1999
DE 19520398 A	12-12-1996	AU 707115 B AU 6300796 A CA 2223821 A CN 1192217 A WO 9641811 A EP 0837871 A JP 11509364 T NO 975772 A NZ 311648 A	01-07-1999 09-01-1997 27-12-1996 02-09-1998 27-12-1996 29-04-1998 17-08-1999 06-02-1998 30-08-1999
WO 9533827 A	14-12-1995	AU 2679095 A EP 0764206 A US 5665554 A	04-01-1996 26-03-1997 09-09-1997
WO 9831840 A	23-07-1998	US 6027945 A AU 6647598 A BR 9805897 A CA 2249393 A EP 0895546 A JP 11509742 T	22-02-2000 07-08-1998 24-08-1999 23-07-1998 10-02-1999 31-08-1999
WO 9618731 A	20-06-1996	AU 706211 B AU 4182996 A CA 2207608 A EP 0796327 A JP 11501504 T	10-06-1999 03-07-1996 20-06-1996 24-09-1997 09-02-1999
WO 9112079 A	22-08-1991	AT 121748 T CA 2071846 A DE 69109275 D DE 69109275 T DK 515484 T EP 0515484 A JP 2703114 B JP 5504095 T US 5523231 A US 5681946 A	15-05-1995 14-08-1991 01-06-1995 24-08-1995 04-09-1995 02-12-1992 26-01-1998 01-07-1993 04-06-1996 28-10-1997